Protein Expression in Samples From Young Patients With Rhabdomyosarcoma

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Corinne M. Linardic, MD, PhD

Duke Cancer Institute

Intervention

protein expression analysis(genetic)

Enrollment

77 enrolled

Eligibility

All sexes

Timeline

2011

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alveolar rhabdomyosarcoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT05304585
  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
  Children's Oncology Group
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209
  Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
  National Cancer Institute (NCI)
• ACTIVE NOT RECRUITINGPHASE3NCT04994132
  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
  Children's Oncology Group
• RECRUITINGPHASE3NCT06669013
  Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
  N.N. Petrov National Medical Research Center of Oncology
• ACTIVE NOT RECRUITINGNCT03296371
  Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
  Children's Oncology Group
• ACTIVE NOT RECRUITINGPHASE3NCT02567435
  Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
  National Cancer Institute (NCI)
• ACTIVE NOT RECRUITINGPHASE2NCT00077285
  Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
  Memorial Sloan Kettering Cancer Center

See all trials for Alveolar rhabdomyosarcoma →